Skip to content

Glaukos GKOS Cost Of Impairment Of Intangible Assets

Cost Of Impairment Of Intangible Assets at other companies

RPM International logo
RPM InternationalRPM
$50K
Invesco logo
InvescoIVZ
$458.1M+3,990%
Teledyne Technologies logo
Teledyne TechnologiesTDY
$750K
Illumina logo
IlluminaILMN
$5.75M-98.8%
Oshkosh logo
OshkoshOSK
$0
Xylem logo
XylemXYL
$500K+100%

Segments

By segment

See full
Development And Commercialization Of Ophthalmic Therapies$112.87M

Other financials

Income statement

See full
Revenue$150.6M+41.2%
Gross profit$117.2M+42.4%
Operating income-$19.9M+4.0%
Net income-$19.8M-9.0%
EPS (diluted)-$0.34-6.3%

Balance sheet

See full
Cash & equivalents$104.2M-8.8%
Total debt$105.9M-1.7%
Total equity$670.9M-12.2%
Total assets$893.3M-7.5%

Cash flow

See full
Operating cash flow-$12.5M+32.4%
CapEx$4.0M+104%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$7.68B+12.3%
Enterprise value$7.68B+12.5%
P/S13.9×-3.0×

Profitability

See full
Gross margin78.1%+2.3pp
Operating margin-36.1%+24.3pp
Net margin-34.3%+4.8pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26.4%+11.1pp
Debt / equity0.2×0.0×
Current ratio5.4×-1.1×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept gkos:CostOfImpairmentOfIntangibleAssets.

The official record: Glaukos’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about Glaukos's cost of impairment of intangible assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Glaukos's cost of impairment of intangible assets?
Glaukos (GKOS) reported cost of impairment of intangible assets of $28.22M in Q4 2025.
What does cost of impairment of intangible assets mean?
A non-cash expense recorded when the value of intangible assets like patents or brands drops significantly.
How do you interpret cost of impairment of intangible assets?
An increase signals that previous investments or acquisitions are not performing as expected, potentially indicating strategic missteps.
How does cost of impairment of intangible assets compare across companies?
Common in R&D-heavy industries like med-tech where acquired technology may fail to meet commercial expectations.